Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Revenue Outlook: What CAGR Is Expected Through 2030?
The global market for managing chemotherapy-induced nausea and vomiting (CINV) has experienced substantial expansion. Projections indicate a progression from a valuation of $3.13 billion in 2025 to $3.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.0%. This upward trajectory during the historical period is underpinned by several key factors, including the heightened deployment of potent emetogenic chemotherapy regimens, a growing understanding of treatment-related adverse effects, enhanced accessibility to sophisticated antiemetic pharmaceuticals, the broadening scope of cancer treatment initiatives, and the refinement of clinical protocols for CINV control.
The market for chemotherapy-induced nausea and vomiting (cinv) treatments is poised for significant expansion in the coming years, projected to reach $4.57 billion by 2030 with a compound annual growth rate (CAGR) of 8.0%. This anticipated growth is fueled by several key factors: escalating demand for advanced antiemetic medications, a greater integration of tailored antiemetic strategies into patient care, the augmentation of ambulatory chemotherapy administration, an intensified commitment to ensuring patients adhere to prescribed treatment plans, and continuous innovations in drug delivery systems designed for prolonged efficacy. Furthermore, prevailing trends shaping this market during the forecast period encompass a greater embrace of multi-drug antiemetic approaches, increased utilization of cinv medications with extended duration of action, a heightened concentration on treatment methodologies that prioritize the patient’s experience, broader implementation of proactive cinv management strategies, and a more pronounced focus on improving overall patient quality of life.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Momentum: Which Factors Are Influencing Demand?
With cancer becoming more common, significant expansion is foreseen for the chemotherapy-induced nausea and vomiting (CINV) market. Cancer signifies aberrant cell proliferation and dissemination within the body. The escalating incidence of cancer globally is spurring greater investment in the creation of superior, specifically targeted anti-emetic interventions to mitigate CINV, an adverse and challenging consequence of cancer treatment. This intensified attention on managing CINV has facilitated progress in deciphering its fundamental processes and pioneering innovative treatments. For example, as reported by the American Cancer Society (ACS) in January 2023, the United States was projected to record 1.9 million new cancer diagnoses (averaging around 5,370 daily) and 609,820 cancer-related fatalities (approximately 1,670 daily) in 2023. Consequently, the rising tide of cancer cases will serve as a key impetus for the growth of the chemotherapy-induced nausea and vomiting (CINV) market.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segment Analysis And Revenue Opportunities
The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends Reshaping Industry Growth
Leading participants within the chemotherapy-induced nausea and vomiting (CINV) sector are actively pursuing novel product developments, including the introduction of fixed intravenous antiemetics, as a strategy to enhance their market standing. A fixed intravenous antiemetic signifies a pre-established dosage of medication delivered via an intravenous route intended to counteract or manage nausea and vomiting, frequently encountered in contexts such as chemotherapy treatment or following surgical procedures. Illustratively, in the month of January 2023, Glenmark Pharmaceuticals Limited, a pharmaceutical entity based in India involved in the production of pharmaceuticals, generic drugs, and over-the-counter items, launched AKYNZEO I.V. within India; this product marked the inaugural fixed intravenous antiemetic formulation specifically engineered for the prevention of chemotherapy-induced nausea and vomiting (CINV). This particular medicinal preparation integrates netupitant alongside palonosetron, addressing the occurrence of both immediate and prolonged periods of nausea and vomiting. It provides the advantage of a single administration, contributes to superior rates of complete symptom resolution, and ultimately elevates the well-being of individuals undergoing cancer therapy. Evidence from clinical investigations indicates its significant utility, especially for patients undergoing chemotherapy regimens characterized by a high emetogenic potential.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Leading Players Shaping Industry Direction
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Access The Complete Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
